Indication
Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii pneumonia is an opportunistic, potentially life-threatening lower respiratory tract infection caused by the atypical fungus *Pneumocystis jirovecii*. Read more about Pneumocystis jirovecii pneumonia
170 drugs 102 manufacturers
Drugs that treat it
Common Pneumocystis jirovecii pneumonia therapies.
ATOVAQUONE
PREDNISONE
PREDNISONE
SULFAMETHOXAZOLE-TRIMETHOPRIM (sulfamethoxazole/trimethoprim)
PREDNISONE
ATOVAQUONE
SULFAMETHOXAZOLE-TRIMETHOPRIM (sulfamethoxazole/trimethoprim)
ATOVAQUONE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPneumocystis jirovecii pneumonia is an opportunistic, potentially life-threatening lower respiratory tract infection caused by the atypical fungus *Pneumocystis jirovecii*.
The disease predominantly affects immunocompromised individuals, most notably people living with advanced human immunodeficiency virus infection or acquired immunodeficiency syndrome, solid organ or hematopoietic stem cell transplant recipients, and patients receiving systemic immunosuppressive therapies such as high-dose corticosteroids or chemotherapy.
Pathophysiologically, the organism adheres to type I alveolar epithelial cells, triggering diffuse alveolar damage and an intra-alveolar foamy, eosinophilic exudate that impairs gas exchange.
Clinically, it manifests as progressive dyspnea, nonproductive cough, fever, and hypoxemia, typically accompanied by bilateral interstitial infiltrates on pulmonary imaging.
- cdc.gov
Pneumocystis jirovecii pneumonia is an opportunistic, potentially life-threatening lower respiratory tract infection caused by the atypical fungus *Pneumocystis jirovecii* The disease predominantly affects immunocompromised individuals, most notably people living with advanced human immunodeficiency virus infection or acquired immunodeficiency syndrome, solid organ or hematopoietic stem cell transplant recipients, and patients receiving systemic immunosuppressive therapies such as high-dose cort...
- nih.gov
Pneumocystis jirovecii pneumonia is an opportunistic, potentially life-threatening lower respiratory tract infection caused by the atypical fungus *Pneumocystis jirovecii* Clinically, it manifests as progressive dyspnea, nonproductive cough, fever, and hypoxemia, typically accompanied by bilateral interstitial infiltrates on pulmonary imaging
- nih.gov
The disease predominantly affects immunocompromised individuals, most notably people living with advanced human immunodeficiency virus infection or acquired immunodeficiency syndrome, solid organ or hematopoietic stem cell transplant recipients, and patients receiving systemic immunosuppressive therapies such as high-dose corticosteroids or chemotherapy
- nih.gov
Pathophysiologically, the organism adheres to type I alveolar epithelial cells, triggering diffuse alveolar damage and an intra-alveolar foamy, eosinophilic exudate that impairs gas exchange
Personalize your experience
Follow Pneumocystis jirovecii pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.